New CT technique could cut radiation while spotting bladder cancer
NCT ID NCT04113603
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two CT urography methods for diagnosing urothelial carcinoma (a type of urinary tract cancer). 352 adults with blood in urine or a history of this cancer will be randomly assigned to receive either a single-bolus or split-bolus CT scan. Researchers will compare how accurately each method detects cancer, and also measure radiation exposure. The goal is to see if the newer split-bolus method works just as well with potentially less radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iodinated contrast medium
- What this could lead to
- If successful, this could identify a simpler, lower-radiation CT scan method that still accurately detects urinary tract cancers.
- What could go wrong
- This is a diagnostic accuracy study, not a treatment trial. Even if one method is better, it won't directly improve patient outcomes or survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Li-Jen Wang
Taoyuan, Ta, 333, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- New antibody aims to unlock immune attack on Hard-to-Treat cancers